Gene Editing
Developers of CRISPR, base- and prime-editing therapeutics.
Leadership as of 2026-10-27: Tracked (too few stocks for a leadership state). Relative to SPY: 5 sessions +4.4pp, 21 sessions +1.3pp, 63 sessions +9.5pp. Participation 67%; 4 of 5 members eligible.
- fewer than 5 eligible members
Economic family: Biotechnology
Member companies
Related themes
- Large-Cap Biopharma: Leading — 21-session vs SPY +6.1pp, participation 75%
- Neuro / CNS: Neutral — 21-session vs SPY −0.2pp, participation 43%
- Molecular Diagnostics: Weakening — 21-session vs SPY +15.9pp, participation 80%
- Immunology & Inflammation: Lagging — 21-session vs SPY −3.6pp, participation 29%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- RNA Therapeutics: Lagging — 21-session vs SPY −4.2pp, participation 40%
- Oncology: Lagging — 21-session vs SPY −8.2pp, participation 32%
- Gene Therapy: Lagging — 21-session vs SPY −16.6pp, participation 0%